ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,487.03
0.25%
US Tech 100
19,430.40
0.14%
다우존스 지수
38,834.86
0.15%
Bitcoin
65,506.45
0.56%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. MIRA Pharmaceuticals Inc (MIRA)

  7. MIRA Pharmaceuticals Inc (MIRA) 뉴스

MIRA

MIRA Pharmaceuticals (MIRA)

MIRA Pharmaceuticals Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:MIRA
일자시간출처헤드라인심볼기업
2024/06/1021:30PR Newswire (US)Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This YearNASDAQ:MIRAMIRA Pharmaceuticals Inc
2024/05/3107:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MIRAMIRA Pharmaceuticals Inc
2024/05/2921:45PR Newswire (US)Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled SubstanceNASDAQ:MIRAMIRA Pharmaceuticals Inc
2024/05/2921:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRAMIRA Pharmaceuticals Inc
2024/05/2306:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MIRAMIRA Pharmaceuticals Inc
2024/05/2121:45PR Newswire (US)MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine AnalogNASDAQ:MIRAMIRA Pharmaceuticals Inc
2024/05/2021:00PR Newswire (US)Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine AnalogNASDAQ:MIRAMIRA Pharmaceuticals Inc
2024/05/1405:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MIRAMIRA Pharmaceuticals Inc
2024/04/0221:00PR Newswire (US)Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND SubmissionNASDAQ:MIRAMIRA Pharmaceuticals Inc
2024/03/2200:04PR Newswire (US)MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific AdvisorNASDAQ:MIRAMIRA Pharmaceuticals Inc
2024/03/0806:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRAMIRA Pharmaceuticals Inc
2024/02/0522:30PR Newswire (US)MIRA Pharmaceuticals Provides Corporate UpdateNASDAQ:MIRAMIRA Pharmaceuticals Inc
2024/01/1806:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRAMIRA Pharmaceuticals Inc
2023/12/2814:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MIRAMIRA Pharmaceuticals Inc
2023/12/2807:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MIRAMIRA Pharmaceuticals Inc
2023/12/2807:27Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MIRAMIRA Pharmaceuticals Inc
2023/12/1906:50Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:MIRAMIRA Pharmaceuticals Inc
2023/12/0422:00PR Newswire (US)MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence SimulationsNASDAQ:MIRAMIRA Pharmaceuticals Inc
2023/12/0207:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRAMIRA Pharmaceuticals Inc
2023/11/2922:00PR Newswire (US)MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%NASDAQ:MIRAMIRA Pharmaceuticals Inc
2023/11/2200:42PR Newswire (US)MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern TimeNASDAQ:MIRAMIRA Pharmaceuticals Inc
2023/11/2200:09PR Newswire (US)MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1aNASDAQ:MIRAMIRA Pharmaceuticals Inc
2023/11/2106:18Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MIRAMIRA Pharmaceuticals Inc
2023/11/2106:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MIRAMIRA Pharmaceuticals Inc
2023/11/2022:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRAMIRA Pharmaceuticals Inc
2023/11/2022:00PR Newswire (US)MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2NASDAQ:MIRAMIRA Pharmaceuticals Inc
2023/09/1821:30PR Newswire (US)MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than PotNASDAQ:MIRAMIRA Pharmaceuticals Inc
2023/09/0521:31PR Newswire (US)MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication EffortsNASDAQ:MIRAMIRA Pharmaceuticals Inc
2023/08/3121:31PR Newswire (US)MIRA Pharmaceuticals to Participate in 6th Annual Cannabinoid-Derived Drug Development SummitNASDAQ:MIRAMIRA Pharmaceuticals Inc
2023/08/3000:39PR Newswire (US)MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern TimeNASDAQ:MIRAMIRA Pharmaceuticals Inc
 검색 관련기사 보기:NASDAQ:MIRA

최근 히스토리

NASDAQ
GOOGL
Alphabet
COIN
BTCUSD
Bitcoin
NYSE
AXP
American Express
NYSE
MRK
Merck
NASDAQ
AAPL
Apple
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
KO
Coca Cola
NASDAQ
AMZN
Amazon.com
AMEX
XLF
Financial Select Sector
SPI
SP500
S&P 500
AMEX
XLV
Health Care Select Sector
NASDAQ
TSLA
Tesla
USOTC
BASFY
BASF (QX)
AMEX
XLE
Energy Select Sector SPDR
FX
USDEUR
US Dollar vs Euro
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유